Loading clinical trials...
Loading clinical trials...
Addition of nivolumab (immune checkpoint inhibitor) to standard chemotherapy (DA-EPOCH-R) may improve outcome in children with primary mediastinal large B-cell lymphoma
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
St. Petersburg State Pavlov Medical University
NCT06003569 · Asthma in Children
NCT06984679 · Cystic Fibrosis (CF), Cystic Fibrosis in Children
NCT07360600 · Parents, Children With Disabilities, and more
NCT06906263 · Anesthesia Complication, Tracheostomy Complications, and more
NCT06260345 · Hospitalized Children, Severe Infection, and more
Dmitry Rogachev National Research Center
Moscow
Pavlov University, RM Gorbacheva Research Institute
Saint Petersburg
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions